Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages
SLAS Discovery · 2024
DOI: 10.1016/j.slasd.2024.100185 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLAS Discovery, 2024. Verfasst von Mozhgan Dehghan Harati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinase 2, Macrophages, Induced Pluripotent Stem Cells, Signal Transduction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Human induced pluripotent stem cell (iPSC)-derived macrophages (IDMs) present a valuable substitute for monocyte-derived macrophages (MDMs) in order to study inflammation pathways in vitro. Through optimization of an IDM differentiation protocol, a six-fold increase in the production yield of myeloid progenitors was achieved. The derived IDMs were further characterized with respect to nucleotide-binding oligomerization domain (NOD) and receptor-interacting serine/threonine-protein kinase 2 (RIPK2) signaling, a key regulatory pathway for autoimmune diseases. The IDM cells recapitulated MDM biology with respect to the proinflammatory chemokine and inflammatory cytokine fingerprint more closely than THP-1 cells. When assessing RIPK2 modulation effect on tumor necrosis factor α (TNF-α), a cardinal mediator of inflammation, a similar pharmacological effect of RIPK2 inhibitors was observed in IDMs and MDMs. Additionally, IDMs and MDMs displayed a similar transcription and pathway profile in response to NOD1/2 stimulation and pharmacological inhibition of RIPK2. In summary, the enhanced myeloid production yield in the improved IDM differentiation protocol offers new opportunities for utilizing physiologically relevant macrophage models in the context of inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
- Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, Connecticut 06877, United States.
- Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
- Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany. Electronic address: ralf.heilker@boehringer-ingelheim.com.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Harati, M. D., King, J., Langer, S., Binder, F., & Heilker, R. (2024). Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages. SLAS Discovery. https://doi.org/10.1016/j.slasd.2024.100185
Vancouver
Harati MD, King J, Langer S, Binder F, Heilker R. Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages. SLAS Discovery. 2024. doi:10.1016/j.slasd.2024.100185
BibTeX
@article{Harati2024,
author = {Harati, Mozhgan Dehghan and King, Jim and Langer, Simon and Binder, Florian and Heilker, Ralf},
title = {Recapitulation of NOD/RIPK2 signaling in iPSC-derived macrophages},
journal = {SLAS Discovery},
year = {2024},
doi = {10.1016/j.slasd.2024.100185}
}
EUVIMED